Professor Amos Burke MB ChB, PhD, MA (Cantab), FRCP Edin, FRCPCH

Professor Amos Burke

Institute of Cancer and Genomic Sciences
Director of Cancer Research UK Clinical Trials Unit
Professor of Paediatric Oncology
Honorary Consultant Paediatric Oncologist

Contact details

View my research portal
Address
Cancer Research UK Clinical Trials Unit (CRCTU)
Institute of Cancer and Genomic Sciences
University of Birmingham
Edgbaston
Birmingham
B15 2TT

Amos Burke is Professor of Paediatric Oncology at the University of Birmingham and an Honorary Consultant Paediatric Oncologist at Birmingham, Women and Children’s Hospital. He is Director of the Cancer Research UK Clinical Trials Unit (CRCTU) and leads research strategy for one of the UK’s largest and an internationally important clinical trials units that delivers a trial portfolio over a wide range of cancers occurring in children, young people and adults. His research is focussed on childhood non-Hodgkin lymphoma. Currently he is Chief Investigator for the innovative platform trial Glo-BNHL for children with relapsed and refractory mature B-cell Non-Hodgkin Lymphoma

Qualifications

  • MA University of Cambridge, 2015
  • Fellowship of the Royal College of Physicians of Edinburgh, 2007
  • Fellowship of the Royal College of Paediatrics and Child Health, 2005
  • PhD, University of Bristol, 2004
  • Membership of the Royal Colleges of Physicians of the United Kingdom, 1996
  • MB ChB, University of Edinburgh, 1991

Biography

Professor Burke is a paediatric oncologist and has held a consultant position in the NHS since 2004. He has a particular interest in childhood lymphomas and chaired the UK paediatric Non-Hodgkin Lymphoma subgroup of the National Cancer Research Institute (NCRI) Lymphoma Clinical Studies Group (2010-2018), remaining an active member (2019-2023). Since 2023 he is Deputy Chair of the UK Children's Research Group (currently supported by the Children's Cancer and Leukemia Group). Since 2005 he has also been a member of the European Intergroup for Childhood Non-Hodgkin Lymphoma and leads on mature B-NHL. Professor Burke has significant experience in clinical trials as both investigator and national lead for the delivery of clinical trials for children and young people with cancer (2011-2021). His laboratory research continues in collaboration with Professor Suzanne Turner in Cambridge where an internationally recognised group for research in childhood NHL has been established. 

Publications

Prokoph N, Matthews JD, Trigg RM, Montes-Mojarro IA, Burke GAA, Fend F, Merkel O, Kenner L, Geoerger B, Johnston R, Murray MJ, Riguad C, Brugières L, Turner SD. Patient-derived xenograft models of ALK+ ALCL reveal preclinical promise for therapy with brigatinib. Br J Haematol. 2023 Jun 25. doi: 10.1111/bjh.18953. Online ahead of print. PMID: 37357529 

Alexander S, Aupérin A, Bomken S, Csóka M, Kazanowska B, Chiang AK, Andres M, Uyttebroeck A, Burke GAA, Zsiros J, Pillon M, Bollard CM, Mussolin L, Verdu-Amoros J, Neven B, Barkauskas DA, Wheatley K, Patte C, Gross TG, Minard-Colin V; Children's Oncology Group; European Intergroup for Childhood Non-Hodgkin's Lymphoma. Effect of rituximab on immune status in children with mature B-cell non-Hodgkin lymphoma: a prespecified secondary analysis of the Inter-B-NHL Ritux 2010 trial. Lancet Haematol. 2023 Jun;10(6):e445-e457. doi: 10.1016/S2352-3026(23)00062-5. Epub 2023 Apr 21. PMID: 37094596

Lueza B, Aupérin A, Rigaud C, Gross TG, Pillon M, Delgado RF, Uyttebroeck A, Amos Burke GA, Zsíros J, Csóka M, Simonin M, Patte C, Minard-Colin V, Bonastre J. Cost-effectiveness analysis alongside the inter-B-NHL ritux 2010 trial: rituximab in children and adolescents with B cell non-Hodgkin's lymphoma. Eur J Health Econ. 2023 Apr 14. doi: 10.1007/s10198-023-01581-y. Epub ahead of print. PMID: 37058173.

Beishuizen A, Mellgren K, Andrés M, Auperin A, Bacon CM, Bomken S, Burke GAA, Burkhardt B, Brugieres L, Chiang AKS, Damm-Welk C, d'Amore E, Horibe K, Kabickova E, Khanam T, Kontny U, Klapper W, Lamant L, Le Deley MC, Loeffen J, Macintyre E, Mann G, Meyer-Wentrup F, Michgehl U, Minard-Colin V, Mussolin L, Oschlies I, Patte C, Pillon M, Reiter A, Rigaud C, Roncery L, Salaverria I, Simonitsch-Klupp I, Uyttebroeck A, Verdu-Amoros J, Williams D, Woessmann W, Wotherspoon A, Wrobel G, Zimmermann M, Attarbaschi A, Turner SD; European Intergroup for Childhood Non-Hodgkin Lymphoma. Improving outcomes of childhood and young adult non-Hodgkin lymphoma: 25 years of research and collaboration within the framework of the European Intergroup for Childhood Non-Hodgkin Lymphoma. Haematol. 2023 Mar;10(3):e213-e224. doi: 10.1016/S2352-3026(22)00374-X. PMID: 36858678 Review.

Burke GAA, Vinti L, Kabickova E, Beishuizen A, Tacyildiz N, Uyttebroeck A, Kang HJ, Luisi F, Minard-Colin V, Burkhardt B, Tamegnon M, Sun S, Curtis M, Deshpande S, Nottage K, Howes AJ, Srinivasan S, Bhojwani D, Norris RE, Cairo MS.  Ibrutinib plus RICE/RVICI for R/R mature B-NHL in children/young adults: SPARKLE trial. Blood Adv. 2023 Feb 28;7(4):602-610. doi: 10.1182/bloodadvances.2022008802. PMID: 36541957

Otth M, Brack E, Kearns PR, Kozhaeva O, Ocokoljic M, Schoot RA, Vassal G; Essential Medicines Group. Essential medicines for childhood cancer in Europe: a pan-European, systematic analysis by SIOPE. Lancet Oncol. 2022 Dec;23(12):1537-1546. doi: 10.1016/S1470-2045(22)00623-4. Epub 2022 Nov 1. PMID: 36332647

Burke GAA, Minard-Colin V, Aupérin A, Alexander S, Pillon M, Delgado R, Zsíros J, Uyttebroeck A, Dartigues P, Miles RR, Kazanowska B, Chiang AK, Haouy S, Bollard CM, Csoka M, Wheatley K, Barkauskas DA, Adamson PC, Vassal G, Patte C, Gross TG. Reply to R. Lakhotia et al. J Clin Oncol. 2022 Jun 20;40(18):2064-2066. doi: 10.1200/JCO.21.02912.Epub 2022 Apr 4. PMID: 35377710

Bomken S, Enshaei A, Schwalbe EC, Mikulasova A, Dai Y, Zaka M, Fung KT, Bashton M, Lim H, Jones L, Karataraki N, Winterman E, Ashby C, Attarbaschi A, Bertrand Y, Bradtke J, Buldini B, Burke GA, Cazzaniga G, Gohring G, De Groot-Kruseman HA, Haferlach C, Nigro LL, Parihar M, Plesa A, Seaford E, Sonneveld E, Strehl S, Van der Velden VH, Rand V, Hunger SP, Harrison CJ, Bacon CM, Van Delft FW, Loh ML, Moppett J, Vormoor J, Walker BA, Moorman AV, Russell LJ. Molecular characterisation and clinical outcome of B-cell precursor acute lymphoblastic leukaemia with IG-MYC rearrangement.  Haematologica. 2022 Apr 28. doi: 10.3324/haematol.2021.280557. Online ahead of print. PMID: 35484682 

Carruthers V, Barnett S, Rees R, Arif T, Slater O, Ramanujachar R, Johnson K, Brown S, Graham C, Burke GAA, Veal GJ. Clinical utility of vinblastine therapeutic drug monitoring for the treatment of infantile myofibroma patients: A case series. Pediatr Blood Cancer. 2022 Jul;69(7):e29722. doi: 10.1002/pbc.29722. Epub 2022 Apr 20. PMID: 35441483 

Trotman J, Armstrong R, Firth H, Trayers C, Watkins J, Allinson K, Jacques TS, Nicholson JC, Burke GAA; Genomics England Research Consortium, Behjati S, Murray MJ, Hook CE, Tarpey P. The NHS England 100,000 Genomes Project: feasibility and utility of centralised genome sequencing for children with cancer.Br J Cancer. 2022 Jul;127(1):137-144. doi: 10.1038/s41416-022-01788-5. Epub 2022 Apr 22. PMID: 35449451

View all publications in research portal